(Q38214155)

31 August 2017

title

Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa (English)

1 reference

31 August 2017

main subject

Pseudomonas aeruginosa

0 references

antibiotic

0 references

author name string

Misagh Alipour

series ordinal

1

1 reference

31 August 2017

Zacharias E Suntres

series ordinal

2

1 reference

31 August 2017

publication date

1 April 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

5

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

409-427

1 reference

Pseudomonas aeruginosa: host defence in lung diseases

31 August 2017

cites work

1 reference

A 4-year surveillance of device-associated nosocomial infections in a neonatal intensive care unit

21 January 2018

1 reference

Pseudomonas aeruginosa: new insights into pathogenesis and host defenses

21 January 2018

1 reference

Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis

21 January 2018

1 reference

The multiple signaling systems regulating virulence in Pseudomonas aeruginosa

21 January 2018

1 reference

The type III secretion system of Pseudomonas aeruginosa: infection by injection

21 January 2018

1 reference

Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung

21 January 2018

1 reference

Early mitochondrial dysfunction, superoxide anion production, and DNA degradation are associated with non-apoptotic death of human airway epithelial cells induced by Pseudomonas aeruginosa exotoxin A.

21 January 2018

1 reference

Pseudomonas exotoxin A: from virulence factor to anti-cancer agent

21 January 2018

1 reference

Metalloproteases from Pseudomonas aeruginosa degrade human RANTES, MCP-1, and ENA-78.

21 January 2018

1 reference

Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function

21 January 2018

1 reference

Virulence factors from Pseudomonas aeruginosa increase lung epithelial permeability

21 January 2018

1 reference

Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection

21 January 2018

1 reference

Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa

21 January 2018

1 reference

Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1

21 January 2018

1 reference

Pseudomonas aeruginosa pyocyanin directly oxidizes glutathione and decreases its levels in airway epithelial cells.

21 January 2018

1 reference

Pseudomonas aeruginosa uses multiple pathways to acquire iron during chronic infection in cystic fibrosis lungs

21 January 2018

1 reference

Pyocyanin-induced toxicity in A549 respiratory cells is causally linked to oxidative stress

21 January 2018

1 reference

Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa

21 January 2018

1 reference

The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin

21 January 2018

1 reference

Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes

21 January 2018

1 reference

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

21 January 2018

1 reference

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

21 January 2018

1 reference

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

21 January 2018

1 reference

Responses of Pseudomonas aeruginosa to antimicrobials

21 January 2018

1 reference

The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.

21 January 2018

1 reference

A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation

21 January 2018

1 reference

Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia.

21 January 2018

1 reference

Update on the treatment of Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum

21 January 2018

1 reference

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment

21 January 2018

1 reference

PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients

21 January 2018

1 reference

Pharmacology of polymyxins: new insights into an 'old' class of antibiotics

21 January 2018

1 reference

Aminoglycoside resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.

21 January 2018

1 reference

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

21 January 2018

1 reference

Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.

21 January 2018

1 reference

Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?

21 January 2018

1 reference

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

21 January 2018

1 reference

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

Liposomal formulations for inhalation

21 January 2018

1 reference

Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements

21 January 2018

1 reference

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

Pharmacological considerations for the proper clinical use of aminoglycosides

21 January 2018

1 reference

A potential role of aminoglycoside resistance in endemic occurrence of Pseudomonas aeruginosa strains in lower airways of mechanically ventilated patients

21 January 2018

1 reference

Aminoglycoside resistance mechanisms in Pseudomonas aeruginosa isolates from non-cystic fibrosis patients in Thailand

21 January 2018

1 reference

Infections in a surgical intensive care unit of a university hospital in Greece

21 January 2018

1 reference

Identification and characterization of bacterial pathogens causing bloodstream infections by DNA microarray

21 January 2018

1 reference

Chronic otorrhoea: spectrum of microorganisms and antibiotic sensitivity in a South African cohort

21 January 2018

1 reference

Pseudomonas aeruginosa: all roads lead to resistance

21 January 2018

1 reference

Pseudomonas aeruginosa - a phenomenon of bacterial resistance

21 January 2018

1 reference

Molecular basis of bacterial outer membrane permeability

21 January 2018

1 reference

The bacterial cell envelope

21 January 2018

1 reference

Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes

21 January 2018

1 reference

PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A

21 January 2018

1 reference

Adaptive resistance to cationic compounds in Pseudomonas aeruginosa.

21 January 2018

1 reference

Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa.

21 January 2018

1 reference

Efflux-mediated drug resistance in bacteria: an update

21 January 2018

1 reference

Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa

21 January 2018

1 reference

Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update.

21 January 2018

1 reference

Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems

21 January 2018

1 reference

Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa

21 January 2018

1 reference

An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal

21 January 2018

1 reference

Bacterial persister cell formation and dormancy.

21 January 2018

1 reference

Aminoglycoside antibiotics induce bacterial biofilm formation

21 January 2018

1 reference

Low hanging fruit in infectious disease drug development

21 January 2018

1 reference

The 'big pharma' dilemma: develop new drugs or promote existing ones?

21 January 2018

1 reference

Liposomal Antioxidants for Protection against Oxidant-Induced Damage

21 January 2018

1 reference

Acute toxicity study of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol, and γ-tocopherol in rats.

21 January 2018

1 reference

NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE.

21 January 2018

1 reference

The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

21 January 2018

1 reference

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections

21 January 2018

1 reference

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Liposomes as delivery systems for antibiotics

21 January 2018

1 reference

The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell

21 January 2018

1 reference

Relevancy of Drug Loading to Liposomal Formulation Therapeutic Efficacy

21 January 2018

1 reference

Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study

21 January 2018

1 reference

In vitro and in vivo activities of ticarcillin-loaded nanoliposomes with different surface charges against Pseudomonas aeruginosa (ATCC 29248)

21 January 2018

1 reference

Development of nanoparticles for antimicrobial drug delivery

21 January 2018

1 reference

Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains

21 January 2018

1 reference

Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats

21 January 2018

1 reference

Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients

21 January 2018

1 reference

Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors

21 January 2018

1 reference

Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia

21 January 2018

1 reference

Antimicrobial efficacy of liposome-encapsulated silver ions and tea tree oil against Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans

21 January 2018

1 reference

Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium

21 January 2018

1 reference

Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells.

21 January 2018

1 reference

Clinical Significance of In Vitro Synergism Between Antibiotics in Gram-Negative Infections

21 January 2018

1 reference

Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.

21 January 2018

1 reference

Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study

21 January 2018

1 reference

Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa.

21 January 2018

1 reference

Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa

21 January 2018

1 reference

Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.

21 January 2018

1 reference

Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa

21 January 2018

1 reference

21 January 2018

1 reference

The characterization and biodistribution of cefoxitin-loaded liposomes

21 January 2018

1 reference

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery

21 January 2018

1 reference

Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

21 January 2018

1 reference

A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers.

21 January 2018

1 reference

Management of antibiotic resistance in the intensive care unit setting

21 January 2018

1 reference

The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection

21 January 2018

1 reference

Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection

21 January 2018

1 reference

Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size

21 January 2018

1 reference

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

21 January 2018

1 reference

Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis

21 January 2018

1 reference

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones

21 January 2018

1 reference

Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin

21 January 2018

1 reference

Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.

21 January 2018

1 reference

The renaissance of polymyxins.

21 January 2018

1 reference

Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection

21 January 2018

1 reference

Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model

21 January 2018

1 reference

New therapies for pneumonia

21 January 2018

1 reference

Antibacterial activity directed isolation of compounds from Punica granatum

21 January 2018

1 reference

Essential oil from Zanthoxylum tingoassuiba loaded into multilamellar liposomes useful as antimicrobial agents.

21 January 2018

1 reference

Localization of antimicrobial peptides on polymerized liposomes leading to their enhanced efficacy against Pseudomonas aeruginosa

21 January 2018

1 reference

oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides

21 January 2018

1 reference

Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity

21 January 2018

1 reference

Personalizing aerosol medicine: development of delivery systems tailored to the individual

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/TDE.14.13

1 reference

31 August 2017

1 reference